Can the new rules limit competition in the sector?

April 1, 2019 amendments to Regulation 10 concerning pharmaceutical product reimbursement were introduced. Can the new rules limit competition in the sector? New rules effective April 1, 2019, allow NHIF to charge pharmaceutical companies if their sales exceed sales (value) from previous periods. The sales numbers will be now monitored every quarter. As introduced, the current rules are expected to bear future revisi
Read More

Understand Changes in Drug Pricing in Bulgaria

On April 1st, 2019, few regulation on drug pricing and inclusion in the positive drug list were updated and in force. Here is a brief summary of the rules that impact directly drug prices in Bulgaria
Read More

Sustainable Joint Procurement

At the National level, Cross-border JP and Organizational experience, and why Europe does not lack organizational expertise.
Read More

The new SPC waiver impact on the biosimilars market in Europe

On February 26, 2019, the Committee on Legal Affairs of the European Parliament approved the draft text of the regulation on supplementary protection certificate SPC waiver. Earlier this year, the Legal Committee of the European Parliament (JURI) has voted in favor of the SPC manufacturing waiver. Read the full article on LinkedIn. With the introduction of SPC waiver for export and stockpiling, generic and biosimilar
Read More

Biosimilars landscape

Biosimilars landscape is evolving in Europe.
Read More

Tendering & Contracting Practice in Europe

Read More
National identity in pharma

National Identity and Pharmaceutical Industry

National identity of a company: the perception of national belonging that we perceive of a company from it's name. For example: the mental impression from the name "British Airways" is that it is a British company.
Read More